Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection
Single Dose Data Demonstrate Significant Reduction in Serum HBsAg Additive Reductions in Serum HBsAg Observed with Repeat Dosing over 3 Months 5 of 6 Patients in Cohort 1 Had Serum HBsAg Reductions of Greater Than 0.5 log10 After 3 Doses Additional Multi- …